Drug
AZD4831 clinical trials
Also written AZD4831.
- studies test it
- 13
- open now
- 0
- in phase 3
- 1
- first study started
- 2016
How studies write it
Studies that test it under each name
Development codes
- AZD4831
- 11
Other names
Studies by the year they started
13 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 5
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses AZD4831 is read from its arms, and is right about nine times in ten.
Testing it · 13
- An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.CompletedPhase 2AstraZenecaNCT05492877Written as Mitiperstat (AZD4831)
- Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%CompletedPhase 2/3AstraZenecaNCT04986202Written as AZD4831
- A Study in Participants With Non-cirrhotic NASH With FibrosisCompletedPhase 2AstraZenecaNCT05638737Written as AZD4831
- Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)CompletedPhase 1/2Mayo ClinicNCT03611153Written as AZD4831 Oral Myeloperoxidase Inhibitor
- Pharmacokinetics of Mitiperstat in Participants With Hepatic ImpairmentCompletedPhase 1AstraZenecaNCT05751759Written as Mitiperstat
- A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.CompletedPhase 1AstraZenecaNCT05457270Written as AZD4831
- A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With ItraconazoleCompletedPhase 1AstraZenecaNCT05236543Written as AZD4831
- A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy VolunteersCompletedPhase 1AstraZenecaNCT04949438Written as AZD4831
- Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of MidazolamCompletedPhase 1AstraZenecaNCT05052710Written as AZD4831
- Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.TerminatedPhase 2AstraZenecaNCT03756285Written as AZD4831
- A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy VolunteersCompletedPhase 1AstraZenecaNCT04232345Written as AZD4831
- A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular DiseaseCompletedPhase 1AstraZenecaNCT03136991Written as AZD4831
- A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male SubjectsTerminatedPhase 1AstraZenecaNCT02712372Written as AZD4831
Codes
What other systems call AZD4831 · ClinicalTrials.gg INT001321
- MeSH (NLM) C000706810AZD4831One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000706810 | AZD4831 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.